REGN

Regeneron Pharmaceuticals, Inc.

Halal Rating :
Comfortable
Last Price $682.41 Last updated:
Market Cap $129.88b
7D Change -4.81%
1 Year Change -27.62%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NASDAQ
Next Earnings Date Oct. 31, 2024

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. The company's product portfolio and pipeline focus on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.

The company's key marketed products include EYLEA (aflibercept) for eye diseases, Dupixent (dupilumab) for allergic diseases, Praluent (alirocumab) for cholesterol management, and Libtayo (cemiplimab) for cancer treatment.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $3.72b $2.56b - $13.8m 0.00% 0.54%
June 30, 2024 $3.55b $2.49b - $14.8m 0.00% 0.59%
March 31, 2024 $3.15b $2.41b - $16.1m 0.00% 0.67%

Company Impact

Help us evaluate Regeneron Pharmaceuticals, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates